skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: SU-G-TeP3-05: In Vitro Demonstration of Endothelial Dose Enhancement Due to Gold Nanoparticles During Low-Voltage Radiotherapy

Abstract

Purpose: Oraya Therapy uses low-voltage, stereotactic, highly targeted X-rays for the treatment of wet age-related macular degeneration (AMD) — offering a new option for patients worldwide. Neovascular endothelial cells play a crucial role in the pathogenesis of this disease. This in-vitro study investigates the potential of gold nanoparticles (GNP) to enhance endothelial cell damage during low-voltage radiotherapy towards potential applications in the treatment of wet-AMD. Methods: Primary human umbilical cord vein endothelium cells (HUVEC) were treated with 1.4 nm sized GNPs for 24 hrs and then irradiated with variable X-ray doses using an Oraya therapy system (100 kVp) or a Small Animal Radiation and Research platform (SARRP) at other beam qualities (up to 220 kVp). Radio-sensitization was assessed by clonogenic assays. Variable concentrations of GNPs (0.05 mg/ml, 0.1 mg/ml, 0.25 mg/ml, 0.5 mg/ml, and 1 mg/ml) where employed. The dose enhancement factor (DEF) was calculated as the ratio of radiation doses required to give the same biological effect (survival factor, SF) with and without GNPs. Results: Preliminary results show DEFs of up to 2.62 for the different combinations of x-ray doses and GNP concentrations and beam qualities. In general the DEF increased with increase in GNP concentration. However, for highmore » doses the effect of GNP becomes less apparent likely due to already high cell kill by the radiation alone. Conclusion: The findings suggest that targeted GNPs can play a significant synergistic role in enhancing stereotactic radiosurgery for wet AMD. The results also provide impetus for ongoing studies to find the optimal synergy between the doses or beam energies and GNPs concentration. This will benefit in-vivo studies towards development of nanoparticle-aided radiotherapy for treatment of wet-AMD and potentially ocular cancers.« less

Authors:
;  [1]; ;  [1];  [2];  [1];  [2]; ;  [3]; ;  [4]
  1. Brigham and Women’s Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (United States)
  2. (United States)
  3. Oraya Therapeutics Inc., Newark, CA (United States)
  4. University of Massachusetts Boston, Boston, MA (United States)
Publication Date:
OSTI Identifier:
22649426
Resource Type:
Journal Article
Resource Relation:
Journal Name: Medical Physics; Journal Volume: 43; Journal Issue: 6; Other Information: (c) 2016 American Association of Physicists in Medicine; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; 61 RADIATION PROTECTION AND DOSIMETRY; BEAMS; BIOLOGICAL EFFECTS; CONCENTRATION RATIO; EYES; GOLD; IN VITRO; IN VIVO; NANOPARTICLES; NEOPLASMS; RADIATION DOSES; RADIOTHERAPY

Citation Formats

Yasmin-Karim, S, Makrigiorgos, GM, Moreau, M, Ngwa, W, University of Massachusetts Lowell, Lowell, MA, Kumar, R, Northeastern University, Boston, MA, Hanlon, J, Arnoldussen, M, Hempstead, J, and Celli, J. SU-G-TeP3-05: In Vitro Demonstration of Endothelial Dose Enhancement Due to Gold Nanoparticles During Low-Voltage Radiotherapy. United States: N. p., 2016. Web. doi:10.1118/1.4957085.
Yasmin-Karim, S, Makrigiorgos, GM, Moreau, M, Ngwa, W, University of Massachusetts Lowell, Lowell, MA, Kumar, R, Northeastern University, Boston, MA, Hanlon, J, Arnoldussen, M, Hempstead, J, & Celli, J. SU-G-TeP3-05: In Vitro Demonstration of Endothelial Dose Enhancement Due to Gold Nanoparticles During Low-Voltage Radiotherapy. United States. doi:10.1118/1.4957085.
Yasmin-Karim, S, Makrigiorgos, GM, Moreau, M, Ngwa, W, University of Massachusetts Lowell, Lowell, MA, Kumar, R, Northeastern University, Boston, MA, Hanlon, J, Arnoldussen, M, Hempstead, J, and Celli, J. Wed . "SU-G-TeP3-05: In Vitro Demonstration of Endothelial Dose Enhancement Due to Gold Nanoparticles During Low-Voltage Radiotherapy". United States. doi:10.1118/1.4957085.
@article{osti_22649426,
title = {SU-G-TeP3-05: In Vitro Demonstration of Endothelial Dose Enhancement Due to Gold Nanoparticles During Low-Voltage Radiotherapy},
author = {Yasmin-Karim, S and Makrigiorgos, GM and Moreau, M and Ngwa, W and University of Massachusetts Lowell, Lowell, MA and Kumar, R and Northeastern University, Boston, MA and Hanlon, J and Arnoldussen, M and Hempstead, J and Celli, J},
abstractNote = {Purpose: Oraya Therapy uses low-voltage, stereotactic, highly targeted X-rays for the treatment of wet age-related macular degeneration (AMD) — offering a new option for patients worldwide. Neovascular endothelial cells play a crucial role in the pathogenesis of this disease. This in-vitro study investigates the potential of gold nanoparticles (GNP) to enhance endothelial cell damage during low-voltage radiotherapy towards potential applications in the treatment of wet-AMD. Methods: Primary human umbilical cord vein endothelium cells (HUVEC) were treated with 1.4 nm sized GNPs for 24 hrs and then irradiated with variable X-ray doses using an Oraya therapy system (100 kVp) or a Small Animal Radiation and Research platform (SARRP) at other beam qualities (up to 220 kVp). Radio-sensitization was assessed by clonogenic assays. Variable concentrations of GNPs (0.05 mg/ml, 0.1 mg/ml, 0.25 mg/ml, 0.5 mg/ml, and 1 mg/ml) where employed. The dose enhancement factor (DEF) was calculated as the ratio of radiation doses required to give the same biological effect (survival factor, SF) with and without GNPs. Results: Preliminary results show DEFs of up to 2.62 for the different combinations of x-ray doses and GNP concentrations and beam qualities. In general the DEF increased with increase in GNP concentration. However, for high doses the effect of GNP becomes less apparent likely due to already high cell kill by the radiation alone. Conclusion: The findings suggest that targeted GNPs can play a significant synergistic role in enhancing stereotactic radiosurgery for wet AMD. The results also provide impetus for ongoing studies to find the optimal synergy between the doses or beam energies and GNPs concentration. This will benefit in-vivo studies towards development of nanoparticle-aided radiotherapy for treatment of wet-AMD and potentially ocular cancers.},
doi = {10.1118/1.4957085},
journal = {Medical Physics},
number = 6,
volume = 43,
place = {United States},
year = {Wed Jun 15 00:00:00 EDT 2016},
month = {Wed Jun 15 00:00:00 EDT 2016}
}